Insider Transactions in Q1 2023 at Pear Therapeutics, Inc. (PEAR)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 15
2023
|
Alison Bauerlein Director |
BUY
Grant, award, or other acquisition
|
Direct |
71,428
+50.0%
|
-
|
|
Feb 15
2023
|
Paul Mango Director |
BUY
Grant, award, or other acquisition
|
Direct |
52,380
+50.0%
|
-
|
|
Feb 15
2023
|
Shivakumar Rajaraman Director |
BUY
Grant, award, or other acquisition
|
Direct |
52,380
+50.0%
|
-
|
|
Feb 15
2023
|
Kirthiga Reddy Director |
BUY
Grant, award, or other acquisition
|
Direct |
61,904
+50.0%
|
-
|
|
Feb 15
2023
|
Nancy M Schlichting Director |
BUY
Grant, award, or other acquisition
|
Direct |
66,666
+50.0%
|
-
|
|
Feb 15
2023
|
Timothy A Wicks Director |
BUY
Grant, award, or other acquisition
|
Direct |
52,380
+50.0%
|
-
|
|
Jan 20
2023
|
Corey Mc Cann President and CEO |
SELL
Open market or private sale
|
Direct |
34,731
-0.42%
|
$34,731
$1.13 P/Share
|
|
Jan 20
2023
|
Yuri Maricich Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,162
-11.42%
|
$12,162
$1.13 P/Share
|
|
Jan 20
2023
|
Katherine Jeffery Chief People Officer |
SELL
Open market or private sale
|
Direct |
7,096
-46.08%
|
$7,096
$1.13 P/Share
|
|
Jan 20
2023
|
Christopherd T Guiffre CFO, COO, Treas., & Asst. Sec. |
SELL
Open market or private sale
|
Direct |
19,540
-39.47%
|
$19,540
$1.13 P/Share
|
|
Jan 20
2023
|
Erin K. Brenner Chief Product Dev. Officer |
SELL
Open market or private sale
|
Direct |
8,690
-16.71%
|
$8,690
$1.13 P/Share
|
|
Jan 20
2023
|
Julia Strandberg Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
12,688
-30.72%
|
$12,688
$1.13 P/Share
|
|
Jan 20
2023
|
Ellen Snow VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
8,027
-25.61%
|
$8,027
$1.13 P/Share
|
|
Jan 20
2023
|
Ronan O'Brien CCO, GC, & Secretary |
SELL
Open market or private sale
|
Direct |
12,162
-39.49%
|
$12,162
$1.13 P/Share
|
|
Jan 14
2023
|
Erin K. Brenner Chief Product Dev. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,000
+29.73%
|
-
|
|
Jan 14
2023
|
Yuri Maricich Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,800
+22.43%
|
-
|
|
Jan 14
2023
|
Katherine Jeffery Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,400
+50.0%
|
-
|
|
Jan 14
2023
|
Ronan O'Brien CCO, GC, & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
30,800
+50.0%
|
-
|
|
Jan 14
2023
|
Julia Strandberg Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,000
+44.41%
|
-
|
|
Jan 14
2023
|
Ellen Snow VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,320
+39.33%
|
-
|
|
Jan 14
2023
|
Christopherd T Guiffre CFO, COO, Treas., & Asst. Sec. |
BUY
Exercise of conversion of derivative security
|
Direct |
49,500
+50.0%
|
-
|
|
Jan 14
2023
|
Corey Mc Cann President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
88,000
+1.06%
|
-
|